LLY ▼ -0.2% - Eli Lilly and Company $LLY - New Phase 3b data on Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together showed improved and durable efficacy at one year in adults with psoriatic disease and obesity Eli Lilly shares declined 0.2% despite the company announcing positive Phase 3b data showing that its psoriasis drug Taltz and obesity medication Zepbound demonstrated improved and durable efficacy when used together in adults with both conditions at the one-year mark. The modest decline suggests the market may have already priced in expectations for this combination therapy data, or investors are weighing the results against other factors affecting the stock today. 31-AUG-2026 07:00 AM ET